CompletedPhase 2NCT00464620
Trial of Dasatinib in Advanced Sarcomas
Studying Alveolar rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Principal Investigator
- Scott Schuetze, MD, PhDUniversity of Michigan
- Intervention
- Dasatinib(drug)
- Enrollment
- 366 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 2007 – 2017
Study locations (20)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- City of Hope, Duarte, California, United States
- Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- Sarcoma Oncology Center, Santa Monica, California, United States
- Washington Cancer Institute, Washington D.C., District of Columbia, United States
- Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
- Kootenai Cancer Center, Coeur d'Alene, Idaho, United States
- Oncology Specialists, Park Ridge, Illinois, United States
- Indiana University Cancer Center, Indianapolis, Indiana, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- +5 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00464620 on ClinicalTrials.govOther trials for Alveolar rhabdomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05304585Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05071209Elimusertib for the Treatment of Relapsed or Refractory Solid TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT04994132A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaChildren's Oncology Group
- RECRUITINGPHASE3NCT06669013Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasN.N. Petrov National Medical Research Center of Oncology
- ACTIVE NOT RECRUITINGNCT03296371Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar RhabdomyosarcomaChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02567435Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT00077285Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk RhabdomyosarcomaMemorial Sloan Kettering Cancer Center